Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F14%3A%230000208" target="_blank" >RIV/26475821:_____/14:#0000208 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patients
Original language description
Poster describing technologies enabling the assessment of circulating tumor DNA (ctDNA). A quantitative ctDNA assay using a massively parallel deep sequencing approach was developed to determine patient ctDNA mutational status. The developed method for quantitative massively parallel deep sequencing of ctDNA for KRAS mutational assessment has reported high clinical sensitivity in plasma and urine. This technical approach is scalable and has the potential for detecting and quantifying a multitude of genomic alterations indicative of therapeutic responsiveness and resistance. Expansion of retrospective colorectal patient cohort described herein will be reported.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13660" target="_blank" >NT13660: Quality evaluation of multimodal treatment in patients with colorectal liver metastatic disease: Mutlicentric study within Czech complex oncology centres</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů